Predictors and Outcomes in Patients With Sickle Cell Disease
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03431935 |
|
Recruitment Status :
Recruiting
First Posted : February 13, 2018
Last Update Posted : July 11, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Children with sickle cell disease (SCD) are living longer with the advent of medical advances such as prophylactic penicillin, chronic transfusion, and hydroxyurea. Despite greater longevity in SCD, the period following the transition from pediatric to adult care is critical; youth aged 18-30 years are at high risk for mortality and have high rates of healthcare utilization, leading to high healthcare costs. As such, health care transition (HCT) programs have been created to prepare patients for adult-centered care and subsequently, improve health outcomes. However, very few programs have been evaluated for effectiveness in achieving optimal health outcomes in SCD. This paucity of program evaluation is attributed to a lack of identifiable predictors and outcomes.
Researchers at St. Jude Children's Research Hospital want to identify factors and patterns of successful HCT. This information will be used to develop approaches to best evaluate HCT interventions and identify areas of improvement of HCT programming.
PRIMARY OBJECTIVE: Describe hospital utilization, treatment adherence, and health-related quality of life in a cohort of patients with sickle cell disease (SCD) who will transfer to adult care during the study period.
SECONDARY OBJECTIVE: Examine the associations between various factors and health care transition (HCT) outcomes.
| Condition or disease |
|---|
| Sickle Cell Disease |
Participants will be asked to complete a set of questions during an outpatient clinic visit at St. Jude or Methodist Adult Comprehensive Sickle Cell Center. The questions ask about sickle cell disease knowledge and self-management skills, access to care, general adjustment, quality of life, and stress. These questions will take about 60 minutes to complete.
Participants will answer questionnaires on a password protected laptop or tablet using a computer program called Audio Computer-Assisted Self-Interviews (ACASI). The laptop or tablet will be kept by the study team. A study team member will be available during this time to address any technical issues or answer any questions. Participants will answer one of the questionnaires verbally, and the study team member will record responses from the questionnaire with paper and pen. Questionnaires given verbally will be audio-recorded and reviewed by the lead researcher or other study team member. The recordings will be destroyed immediately after review. No transcript or written record of the recordings will be made. Study members will meet five times with each participant during regularly-scheduled clinical visits over a two year period.
Two institutions will collaborate in the proposed project. St. Jude Children's Research Hospital (St. Jude) and the Methodist Comprehensive Sickle Cell Center will be the primary source of participants. Faculty from the University of Memphis, Department of Psychology, will be involved in methodological considerations and analyzing the data.
| Study Type : | Observational |
| Estimated Enrollment : | 146 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | Longitudinal Examination of Predictors and Outcomes of Sickle Cell Disease Healthcare Transition |
| Actual Study Start Date : | July 31, 2018 |
| Estimated Primary Completion Date : | January 2024 |
| Estimated Study Completion Date : | January 2026 |
- Number of emergency room/hospital admissions in the previous 12 months [ Time Frame: Once, at age 19 ]The primary objective will utilize data collected at age 19 years, 0 months (±2 months), the age participants will have transferred to adult care. This data will come from participants enrolled between the ages of 17 years, 0 months and 19 years, 0 months.
- Percent of clinic visits completed in the previous 12 months [ Time Frame: Once, at age 19 ]The primary objective will utilize data collected at age 19 years, 0 months (±2 months), the age participants will have transferred to adult care. This data will come from participants enrolled between the ages of 17 years, 0 months and 19 years, 0 months.
- Percent hydroxyurea prescription refill rate [ Time Frame: Once, at age 19 ]The primary objective will utilize data collected at age 19 years, 0 months (±2 months), the age participants will have transferred to adult care. This data will come from participants enrolled between the ages of 17 years, 0 months and 19 years, 0 months.
- Health-related quality of life as assessed by the PedsQL [ Time Frame: Once, at age 19 ]The primary objective will utilize data collected at age 19 years, 0 months (±2 months), the age participants will have transferred to adult care. This data will come from participants enrolled between the ages of 17 years, 0 months and 19 years, 0 months.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 16 Years to 20 Years (Child, Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Diagnosis of sickle cell disease (all genotypes).
- Age 16.0 - 20.99 years at initial assessment.
- Primary language is English.
Exclusion Criteria:
- Participant unable to complete the questionnaires due to refusal, current acute illness (e.g., pain crisis), or significant cognitive impairment as judged by health care providers at the SCD clinic.
- Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03431935
| Contact: Jerlym Porter, PhD, MPH | 866-278-5833 | referralinfo@stjude.org |
| United States, Tennessee | |
| Methodist Adult Comprehensive Sickle Cell Center | Recruiting |
| Memphis, Tennessee, United States, 38104 | |
| Contact: Jerlym Porter, PhD, MPH 901-595-4357 referralinfo@stjude.org | |
| Principal Investigator: Jerlym Porter, PhD, MPH | |
| St. Jude Children's Research Hospital | Recruiting |
| Memphis, Tennessee, United States, 38105 | |
| Contact: Jerlym Porter, PhD, MPH 866-278-5833 referralinfo@stjude.org | |
| Principal Investigator: Jerlym Porter, PhD, MPH | |
| Principal Investigator: | Jerlym Porter, PhD, MPH | St. Jude Children's Research Hospital |
| Responsible Party: | St. Jude Children's Research Hospital |
| ClinicalTrials.gov Identifier: | NCT03431935 |
| Other Study ID Numbers: |
LEAPS K01HL125495-01A1 ( U.S. NIH Grant/Contract ) |
| First Posted: | February 13, 2018 Key Record Dates |
| Last Update Posted: | July 11, 2022 |
| Last Verified: | July 2022 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Health Care Transition Adolescent Young Adult |
|
Anemia, Sickle Cell Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia |
Hematologic Diseases Hemoglobinopathies Genetic Diseases, Inborn |